Sign Out
There is some absorption of Minoxidil from the skin and the potential exists for systemic effect such as tachycardia, angina, edema or potentiation of the orthostatic hypotension produced by Guanethidine. Patients should be observed periodically for any suggestion of systemic effects of Minoxidil. In the event of systemic side effects discontinue administration of this product. If necessary, fluid retention and edema can be managed with diuretic treatment. Tachycardia and angina can be controlled by administration of beta-adrenergic blocking drugs or other sympathetic nervous system suppressants.
Though not expected, Finasteride on percutaneous absorption can suppress the serum DHT levels and may cause systemic side effects i.e. decreased libido, erectile dysfunction, ejaculation disorders, breast tenderness or enlargement and testicular pain. Patients should be observed periodically for any suggestion of such a systemic effect. Special caution should be taken for the patients with liver function abnormalities, because large amounts of Finasteride is metabolized in the liver.
Patients with Underlying Cardiovascular Disease: Since this product contains Minoxidil, patients should not use this product if they have a history of underlying coronary artery disease, cardiac dysrhythmias, congestive heart failure, or valvular heart disease. Patients with hypertension, including those under treatment with antihypertensive agents, should be monitored closely and their medication adjusted if necessary. This product should be used with caution in patients with history of any other cardiovascular disease or if present.
Effect on laboratory tests result: Serum Prostate Specific Antigen (PSA) Levels: Percutaneous absorption of Finasteride may affect serum PSA levels. These shall be taken into account for proper interpretation of serum PSA when evaluating men treated with this product.
Use in Pregnancy and Lactation: This product should not be used by pregnant or nursing women.
This is due lo the ability of Type II 5-α-reductase inhibitors to inhibit the conversion of testosterone to DHT. Finasteride may cause abnormalities of the external genital of male fetus of a pregnant woman who receives Finasteride.
Use in Children: Safety and effectiveness of this product in patients under 18 years old has not been established.
Geriatrics: Studies involving subject over the age of 60 years have not been performed hence the safety and effectiveness of this product in these patients has not been established.
